Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07128199 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
A Phase 3 study of Lung Cancer and EGFR, sponsored by Taiho Oncology.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT07128199: Recruiting Phase 3 study of Lung Cancer and EGFR, sponsored by Taiho Oncology.
NCT07128199 is a Phase 3 study of Lung Cancer and EGFR that is actively recruiting participants, run by Taiho Oncology. The registered enrollment target is 360 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07128199, a Phase 3 study of Lung Cancer and EGFR, is actively recruiting participants, sponsored by Taiho Oncology.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of zipalertinib combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in participants with early stage (stage IB-IIIA) resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG TAS6417
- DRUG Zipalertinib Matching-placebo
Study Locations (20)
Buenos Aires
- Instituto Argentino de Diagnóstico y Tratamiento - Ciudad Autónoma de Buenos Aires
- Centro de Investigación Pergamino SA - Pergamino
- Hospital Universitario Austral - Pilar
Florida
- D&H Cancer Research Center - Margate - Margate
- Alpha Oncology Research - Orange City
Michigan
- Profound Research LLC at Michigan Hematology and Oncology Consultants - Dearborn
- Henry Ford Health System - Detroit
New York
- Perlmutter Cancer Center - 34th Street - New York
- Memorial Sloan Kettering Cancer Center - New York - New York
New South Wales
- Bankstown-Lidcombe Hospital - Bankstown
- GenesisCare - North Shore - St Leonards
Alaska
- Alaska Oncology and Hematology - Anchorage
California
- City of Hope Comprehensive Cancer Center - Duarte - Duarte
District of Columbia
- Georgetown University School of Medicine - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2025-12-22 |
| Est. Completion | 2032-10-01 |
| Phase | Phase 3 |
What NCT07128199 shows while recruiting
NCT07128199 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (61% lower).
The record links to 8 conditions, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT07128199 names 20 study sites across 14 states, led by Buenos Aires, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT07128199 about?
NCT07128199 is a clinical study titled "A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection". The purpose of this study is to compare the efficacy of zipalertinib combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in participants with early stage (stage IB-IIIA) resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor...
What is the current status of trial NCT07128199?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2025-12-22. Estimated completion is 2032-10-01.
What conditions does trial NCT07128199 study?
This clinical trial studies the following conditions: Lung Cancer, EGFR, NSCLC, Stage IB-IIIA, Adjuvant, Post-surgical.
What interventions are being tested in trial NCT07128199?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), TAS6417 (DRUG), Zipalertinib Matching-placebo (DRUG).
Who is sponsoring clinical trial NCT07128199?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07128199 being conducted?
This trial has 20 study locations across Alaska, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07128199's enrollment target sits among peer trials
360 87th of 409 higher than 322 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
-
National Lung Screening Trial (NLST) Screening
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI